PARD - Poniard Pharmaceuticals, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue---
Cost of Revenue---
Gross Profit---
Operating Expenses
Research Development7,97525,73934,714
Selling General and Administrative18,35714,69814,443
Non Recurring1,6262,5412,541
Total Operating Expenses---
Operating Income or Loss-27,958-42,978-49,157
Income from Continuing Operations
Total Other Income/Expenses Net117406592
Earnings Before Interest and Taxes-27,841-42,572-48,565
Interest Expense2,2103,1433,143
Income Before Tax-30,051-45,715-48,565
Income Tax Expense---
Minority Interest---
Net Income From Continuing Ops-30,051-45,715-48,565
Non-recurring Events
Discontinued Operations---
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income-30,051-45,715-48,565
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares-30,787-46,215-49,065